Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) insider Peter Rahmer sold 20,450 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $7.06, for a total value of $144,377.00. Following the transaction, the insider now owns 432,425 shares of the company’s stock, valued […]
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Relay Therapeutics Announces Clinical Trial Collaboration globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Rhenman & Partners Asset Management AB grew its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 105.3% during the fourth quarter, HoldingsChannel reports. The firm owned 390,000 shares of the company’s stock after acquiring an additional 200,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Relay Therapeutics were worth […]
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report)’s share price fell 6.5% during trading on Wednesday . The stock traded as low as $6.29 and last traded at $6.33. 68,135 shares traded hands during trading, a decline of 94% from the average session volume of 1,156,340 shares. The stock had previously closed at $6.77. Analyst […]